3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase NA
1
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Venous Thromboembolism
8
Venous Thrombosis
5
Pulmonary Embolism
5
Neoplasms
4
Thromboembolism
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Thrombosis
1
Thrombophilia
1
Thrombocythemia, Essential
1
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Pancreatic Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Monoclonal Gammopathy of Undetermined Significance
1
Mesenteric Ischemia
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Interventions
Injections
2
enoxaparin sodium
1
bemiparin
1
apixaban
1
Phlebotomy
1
Hydroxyurea
1
Heparin
1
Dalteparin
1
Clopidogrel
1
Aspirin
1
Anticoagulants
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Thrombosis
×
Dalteparin
×
Clear all
NCT06153394
2024-04-23
PRIORITY
Western University, Canada
Phase 3
Not yet recruiting
50 enrolled